Anticonvulsant News and Research

RSS

Gabapentin drug helps people to quit cannabis

Scientists at The Scripps Research Institute have found clinical evidence that the drug gabapentin, currently on the market to treat neuropathic pain and epilepsy, helps people to quit smoking marijuana.

24 Apr 2012

Study shows underutilization of epilepsy surgery

Ten years ago, a landmark clinical trial in Canada demonstrated the unequivocal effectiveness of brain surgeries for treating uncontrolled epilepsy, but since then the procedure has not been widely adopted-in fact, it is dramatically underutilized according to a new study from the University of California, San Francisco (UCSF).

24 Apr 2012

State capitols: Social issues a hot topic; Iowa short on time for state budget; Kansas advances drug bills

Legislatures in Iowa and Kansas consider bills on health care, while Stateline looks at the social issues debates going on in many state capitols around the nation.

3 Apr 2012

SK Biopharmaceuticals' YKP3089 receives Korea Drug Development Fund

South Korean pharmaceutical company SK Biopharmaceuticals announced that the lead drug, YKP3089, from its drug development program for the treatment of refractory epilepsy, has been awarded funding from the Korea Drug Development Fund to support clinical development for the next three years.

3 Mar 2012

Substituting antiepileptic drugs may lead to increase in risk of epilepsy

The substitution of brand-name antiepileptic drugs with cheaper generic equivalents has been an ongoing point of contention among doctors, federal officials and people with epilepsy.

18 Feb 2012

Midazolam autoinjector pen more effective in treating status epilepticus

Results have just been released from an NIH study conducted at multiple sites, including the University of Kentucky, indicating that an autoinjector pen is a faster and possibly more effective way for emergency medical personnel to treat serious seizures.

17 Feb 2012

Intramuscular midazolam effective in treating status epilepticus

Drug delivery directly into muscle using an autoinjector is faster and may be more effective in stopping prolonged seizures, according to a study sponsored by the National Institutes of Health and conducted by a Wayne State University School of Medicine researcher.

17 Feb 2012

Epilepsy community concerned over AHRQ's AED drug comparison study

Leading representatives of the American Epilepsy Society, American Academy of Neurology, and the Epilepsy Foundation today reported they have grave concerns about the implications and potential misuse of the anticonvulsant (AED) drug comparisons study recently released by the U.S. Agency for Health Research and Quality.

17 Feb 2012

Rapid intramuscular injection of midazolam drug is safe, effective for status epilepticus

When a person is experiencing a prolonged convulsive seizure, quick medical intervention is critical. With every passing minute, the seizure becomes harder to stop, and can place the patient at risk of brain damage and death. This is why paramedics are trained to administer anticonvulsive medications as soon as possible -- traditionally giving them intravenously before arriving at the hospital.

16 Feb 2012

Midazolam autoinjector may effectively treat status epilepticus

Drug delivery into muscle using an autoinjector, akin to the EpiPen used to treat serious allergic reactions, is faster and may be a more effective way to stop status epilepticus, a prolonged seizure lasting longer than five minutes, according to a study sponsored by the National Institutes of Health. Status epilepticus is a potentially life-threatening emergency that causes 55,000 deaths each year.

16 Feb 2012

Oak Pharmaceuticals acquires three Lundbeck hospital-based injectables

Akorn, Inc., a niche generic pharmaceutical company, today announced that its wholly-owned subsidiary, Oak Pharmaceuticals, has acquired three off-patent, branded, hospital-based injectables from the US subsidiary of H. Lundbeck A/S.

23 Dec 2011

Prenatal exposure to valproate may increase risk of autism in children

Investigators in a population-based study in Denmark reporting today at the American Epilepsy Society's 65th annual meeting have found there is an increased risk of autism spectrum disorder and childhood autism in children born of mothers who are exposed to the anticonvulsant valproate during pregnancy.

6 Dec 2011

Bromide shows promise against SCN1A-associated Dravet syndrome with intractable seizures

In the mid-nineteenth century Charles Locock, physician to Queen Victoria, introduced bromide as the first effective treatment for epilepsy. The drug was little used in treating the disorder until 1868, however, when its efficacy against seizures was first demonstrated in a clinical trial. Bromide was the sole anticonvulsant available until 1912 and the introduction of phenobarbital.

5 Dec 2011

Scientists turn drug-disease match makers

In a new medical breakthrough American researchers have devised a drug-disease matchmaking program that mines databases for potentially useful new treatment combinations and have actually turned up two so far, said a study on Wednesday.

18 Aug 2011

UCSF neurosurgery shows promise against severe epilepsy

Two-thirds of people with severe and otherwise untreatable epilepsy were completely cured of their frequent seizures after undergoing neurosurgery at the University of California, San Francisco Medical Center, according to a new study that examined 143 of these patients two years after their operations.

22 Jul 2011

Excess brain activity in aMCI patients contributes to brain dysfunction underlying memory loss

An existing anti-seizure drug improves memory and brain function in adults with a form of cognitive impairment that often leads to full-blown Alzheimer's disease, a Johns Hopkins University study has found.

21 Jul 2011

UW C4C, Pharmigene execute licensing agreement for warfarin personalized medicine technology

The University of Washington Center for Commercialization and Pharmigene, a leader in advancing personalized medicine and reducing severe adverse reactions to drugs through genetic-based diagnostic solutions, today announced the execution of a licensing agreement between the parties.

18 May 2011

Marinus initiates ganaxolone Phase 2 trial in posttraumatic stress disorder

Marinus Pharmaceuticals, Inc., the leader in the development of neurosteroids for central nervous system disorders, today announced commencement of a proof-of-concept clinical trial of its lead candidate ganaxolone for the treatment of posttraumatic stress disorder.

22 Apr 2011

Alternative anti-inflammatory approach to epilepsy management

If common anticonvulsant drugs fail to manage epileptic seizures, then perhaps the anti-inflammatory route is the way to go. That's according to Mattia Maroso and colleagues from the Mario Negri Institute for Pharmacological Research in Milan, Italy, who found that giving mice repeated doses of a specific enzyme inhibitor significantly reduced both chronic epileptic activity and acute seizures.

28 Mar 2011

Researchers identify low-dose, two-drug cocktail that reduces noise-induced hearing loss in mice

Whether on a battlefield, in a factory or at a rock concert, noise-induced hearing loss is one of the most common hazards people face. Researchers at Washington University School of Medicine in St. Louis have identified a low-dose, two-drug cocktail that reduces hearing loss in mice when given before they are exposed to loud noise. The drugs, already FDA-approved for other conditions, also treat hearing loss after noise exposure.

23 Feb 2011